Corvus Pharmaceuticals
CRVS
57 hedge funds and large institutions have $284M invested in Corvus Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 29 increasing their positions, 12 reducing their positions, and 6 closing their positions.
142% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 12
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
4% more funds holding
Funds holding: 55 → 57 (+2)
2.1% more ownership
Funds ownership: 86.65% → 88.75% (+2.1%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less capital invested
Capital invested by funds: $288M → $284M (-$3.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
Cowen Inc
New York
|
+$5.97M |
| 2 |
BlackRock
New York
|
+$4.27M |
| 3 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
+$908K |
| 4 |
State Street
Boston,
Massachusetts
|
+$783K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$684K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.9M |
| 2 |
JP Morgan Chase
New York
|
-$1.16M |
| 3 |
Renaissance Technologies
New York
|
-$1.14M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$903K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$824K |
CRVS Hedge Fund Activity: Q2 2018 in Review
57 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q2 2018, worth a combined $284M — down 1.1% from $288M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CRVS positions and 6 closed out — a net gain of 2 holders — while 29 added to existing stakes and 12 trimmed.
The largest buyer was Cowen Inc, opening a new position worth an estimated $5.97M. The largest seller was Millennium Management, cutting an estimated $2.9M.
- 57 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q2 2018, up from 55 in Q1 2018.
- Funds reported $284M of Corvus Pharmaceuticals stock for Q2 2018, down 1.1% quarter-over-quarter.
- 8 funds opened new Corvus Pharmaceuticals positions in Q2 2018 and 6 closed out, a net change of +2 holders.
- The largest Corvus Pharmaceuticals buyer in Q2 2018 was Cowen Inc, an estimated $5.97M added.
- The largest Corvus Pharmaceuticals seller in Q2 2018 was Millennium Management, an estimated $2.9M sold.
Based on aggregated 13F filings for Q2 2018.